TD Asset Management
CBAY

TD Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

TD Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-157,556
Closed -$3.72M – 1455
2023
Q4 		$3.72M Buy
157,556
+65,600
+71% +$1.17M ﹤0.01% 825
2023
Q3 		$1.37M Buy
+91,956
New +$1.22M ﹤0.01% 1064
2018
Q4 		– Sell
-22,100
Closed -$245K – 1450
2018
Q3 		$245K Sell
22,100
-10,200
-32% -$127K ﹤0.01% 1384
2018
Q2 		$433K Sell
32,300
-4,467
-12% -$55.9K ﹤0.01% 1290
2018
Q1 		$478K Buy
+36,767
New +$457K ﹤0.01% 1211

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TD Asset Management's CBAY Position: Q1 2024 in Review

TD Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 157,556 shares — an estimated $3.72M sold.

TD Asset Management first reported a position in CBAY in Q1 2018 and held it in 5 quarters. The position peaked at $3.72M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • TD Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • TD Asset Management sold 157,556 Cymabay Therapeutics shares in Q1 2024, an estimated $3.72M.
  • TD Asset Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 5 quarters.
  • TD Asset Management's Cymabay Therapeutics position peaked at $3.72M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on TD Asset Management's 13F filing for Q1 2024, filed 8 May 2024.